SHL Telemedicine Ltd. (SWX:SHLTN)
1.070
0.00 (0.00%)
Oct 2, 2026, 5:30 PM CET
SHL Telemedicine Revenue
SHL Telemedicine had revenue of $31.32M USD in the half year ending June 30, 2026, with 12.39% growth. This brings the company's revenue in the last twelve months to $62.10M, up 9.27% year-over-year. In the year 2025, SHL Telemedicine had annual revenue of $58.69M with 3.37% growth.
Revenue (ttm)
$62.10M
Revenue Growth
+9.27%
P/S Ratio
0.79
Revenue / Employee
$118.06K
Employees
526
Market Cap
39.65M CHF
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 58.69M | 1.92M | 3.37% |
| Dec 31, 2024 | 56.78M | -296.00K | -0.52% |
| Dec 31, 2023 | 57.08M | -1.92M | -3.26% |
| Dec 31, 2022 | 59.00M | 9.42M | 18.99% |
| Dec 31, 2021 | 49.58M | 9.42M | 23.45% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 62.96B |
| Novartis AG | 45.81B |
| Lonza Group AG | 6.87B |
| Galderma Group AG | 4.79B |
| Ascom Holding AG | 291.90M |
| Curatis Holding AG | 13.50M |
| Newron Pharmaceuticals | 9.62M |
| BioVersys AG | 4.62M |
SHL Telemedicine News
- 9 months ago - Value Base Ltd. Acquires Significant Stake in SHL Telemedicine Ltd. - GuruFocus
- 1 year ago - DocGo and SHL Telemedicine Partner to Revolutionize Patient Access to Cardiovascular Care - Business Wire
- 2 years ago - SHL Telemedicine to Appoint David Arnon as CEO of SHL Telemedicine - Business Wire
- 2 years ago - SHL Telemedicine Confirms Discussions Regarding a Possible Investment in its Israeli Activity - Business Wire
- 2 years ago - SHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood Test - Business Wire
- 2 years ago - SHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft Launch - Business Wire
- 2 years ago - SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones - Business Wire
- 2 years ago - Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine's SmartHeart® in Post-ACS Patient Care - Business Wire